LV12449B - WATER SUSPENSION FOR HUMAN USE - Google Patents

WATER SUSPENSION FOR HUMAN USE Download PDF

Info

Publication number
LV12449B
LV12449B LVP-99-109A LV990109A LV12449B LV 12449 B LV12449 B LV 12449B LV 990109 A LV990109 A LV 990109A LV 12449 B LV12449 B LV 12449B
Authority
LV
Latvia
Prior art keywords
suspension
loteprednol etabonate
aqueous suspension
nasal
microcrystalline cellulose
Prior art date
Application number
LVP-99-109A
Other languages
English (en)
Latvian (lv)
Other versions
LV12449A (lv
Inventor
Koji Doi
Original Assignee
Bodor,Nicholas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor,Nicholas filed Critical Bodor,Nicholas
Publication of LV12449A publication Critical patent/LV12449A/xx
Publication of LV12449B publication Critical patent/LV12449B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
LVP-99-109A 1997-01-16 1999-07-15 WATER SUSPENSION FOR HUMAN USE LV12449B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1966497 1997-01-16
PCT/JP1998/000108 WO1998031343A2 (en) 1997-01-16 1998-01-14 Aqueous suspension for nasal administration of loteprednol

Publications (2)

Publication Number Publication Date
LV12449A LV12449A (lv) 2000-04-20
LV12449B true LV12449B (en) 2000-09-20

Family

ID=12005518

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-109A LV12449B (en) 1997-01-16 1999-07-15 WATER SUSPENSION FOR HUMAN USE

Country Status (33)

Country Link
US (1) US6368616B1 (zh)
EP (1) EP0973501B1 (zh)
KR (1) KR100471708B1 (zh)
CN (1) CN1126535C (zh)
AR (1) AR011773A1 (zh)
AT (1) ATE249205T1 (zh)
AU (1) AU730953C (zh)
BR (1) BR9806771A (zh)
CA (1) CA2278025C (zh)
CZ (1) CZ294919B6 (zh)
DE (1) DE69818026T2 (zh)
DK (1) DK0973501T3 (zh)
EA (1) EA001775B1 (zh)
ES (1) ES2206880T3 (zh)
HK (1) HK1026138A1 (zh)
HU (1) HU226613B1 (zh)
ID (1) ID21892A (zh)
IL (1) IL130979A0 (zh)
LT (1) LT4677B (zh)
LV (1) LV12449B (zh)
MX (1) MXPA99006628A (zh)
NO (1) NO324619B1 (zh)
NZ (2) NZ336990A (zh)
PL (1) PL190753B1 (zh)
PT (1) PT973501E (zh)
RS (1) RS49701B (zh)
SI (1) SI20057A (zh)
SK (1) SK283164B6 (zh)
TR (1) TR199901663T2 (zh)
TW (1) TW503113B (zh)
UA (1) UA52722C2 (zh)
WO (1) WO1998031343A2 (zh)
ZA (1) ZA98303B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
ATE331532T1 (de) * 1998-08-26 2006-07-15 Teijin Ltd Pulverförmige pernasale mittel
DE19947235A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
NZ530227A (en) * 2001-06-18 2006-09-29 Noven Pharma Enhanced drug delivery in transdermal systems
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
JP4893305B2 (ja) * 2003-06-19 2012-03-07 ボーダー、ニコラス・エス 局所又は他の局部投与用のソフト抗炎症性ステロイドの活性及び／又は作用持続性の増強
DE602004008083T2 (de) * 2003-06-19 2008-04-24 Nicholas S. Gainsville Bodor Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
DE602005016392D1 (de) 2004-03-25 2009-10-15 Bausch & Lomb Verwendung von loteprednoletabonat zur behanldung von trockenen augen
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
KR20140069210A (ko) 2011-09-22 2014-06-09 보오슈 앤드 롬 인코포레이팃드 안과적 겔 조성물
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액

Also Published As

Publication number Publication date
WO1998031343A3 (en) 1998-09-17
ATE249205T1 (de) 2003-09-15
SK283164B6 (sk) 2003-03-04
AU5495298A (en) 1998-08-07
SK94899A3 (en) 2000-05-16
AR011773A1 (es) 2000-09-13
CN1250370A (zh) 2000-04-12
IL130979A0 (en) 2001-01-28
CZ237499A3 (cs) 2000-01-12
NO993453D0 (no) 1999-07-13
PL190753B1 (pl) 2006-01-31
CA2278025C (en) 2005-09-06
HU226613B1 (en) 2009-04-28
ES2206880T3 (es) 2004-05-16
KR20000070214A (ko) 2000-11-25
LT99100A (en) 2000-02-25
WO1998031343A2 (en) 1998-07-23
UA52722C2 (uk) 2003-01-15
DE69818026D1 (de) 2003-10-16
MXPA99006628A (es) 2005-01-10
CA2278025A1 (en) 1998-07-23
AU730953B2 (en) 2001-03-22
US6368616B1 (en) 2002-04-09
DE69818026T2 (de) 2004-07-08
LT4677B (lt) 2000-07-25
EP0973501A2 (en) 2000-01-26
KR100471708B1 (ko) 2005-03-07
YU36199A (sh) 2002-09-19
TR199901663T2 (xx) 1999-09-21
DK0973501T3 (da) 2004-01-19
RS49701B (sr) 2007-12-31
LV12449A (lv) 2000-04-20
CZ294919B6 (cs) 2005-04-13
EP0973501B1 (en) 2003-09-10
SI20057A (sl) 2000-04-30
HUP0002473A2 (hu) 2000-12-28
NZ509908A (en) 2004-12-24
HK1026138A1 (en) 2000-12-08
ZA98303B (en) 1998-07-20
AU730953C (en) 2002-02-07
HUP0002473A3 (en) 2001-01-29
ID21892A (id) 1999-08-05
NZ336990A (en) 2001-03-30
EA199900659A1 (ru) 2000-02-28
EA001775B1 (ru) 2001-08-27
TW503113B (en) 2002-09-21
PT973501E (pt) 2004-02-27
BR9806771A (pt) 2000-05-16
CN1126535C (zh) 2003-11-05
NO324619B1 (no) 2007-11-26
PL334614A1 (en) 2000-03-13
NO993453L (no) 1999-07-13

Similar Documents

Publication Publication Date Title
AU730953C (en) Aqueous suspension for nasal administration
EP0742714B1 (en) Liquid pharmaceutical compositions comprising thyroid hormones
EP0938896A1 (en) Autoclavable pharmaceutical compositions containing a chelating agent
JP3597333B2 (ja) 急性鼻炎を処置するための医薬製剤
HU226527B1 (hu) Készítmények nátha kezelésére
CA2159288A1 (en) Aqueous nasal suspension
JP4453987B2 (ja) 点鼻用水性懸濁液
TW565456B (en) Method of reducing irritativeness of surface active agents and aqueous compositions with reduced irritativeness
US20090142321A1 (en) Opthalmic composition
JP2003055201A (ja) ビタミンａ類含有可溶化組成物及びビタミンａ類の安定化方法
JPH08151332A (ja) 点鼻用水性懸濁液
JP2001131055A (ja) 液剤、液剤の白濁解消方法及び液剤の経粘膜吸収促進方法
JPH1036255A (ja) 眼圧降下用点眼剤
IT9048064A1 (it) Composizioni farmaceutiche a base di calcitonina somministrabili per via nasale in terapia umana
NZ616149B2 (en) Nasal Pharmaceutical Formulation Comprising Fluticasone
NZ616149A (en) Nasal pharmaceutical formulation comprising fluticasone